Chagan Larisa, Bernstein Diane, Cheng Judy W M, Kirschenbaum Harold L, Rozenfeld Vitalina, Caliendo Gina C, Meyer Joanne, Mehl Bernard
Division of Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA.
BMC Complement Altern Med. 2005 Mar 3;5:4. doi: 10.1186/1472-6882-5-4.
The use of complementary and alternative products including Biological Based Therapy (BBT) has increased among patients with various medical illnesses and conditions. The studies assessing the prevalence of BBT use among patients with cardiovascular diseases are limited. Therefore, an evaluation of BBT in this patient population would be beneficial. This was a survey designed to determine the effects of demographics on the use of Biological Based Therapy (BBT) in patients with cardiovascular diseases. The objective of this study was to determine the effect of the education level on the use of BBT in cardiovascular patients. This survey also assessed the perceptions of users regarding the safety/efficacy of BBT, types of BBT used and potential BBT-drug interactions.
The survey instrument was designed to assess the findings. Patients were interviewed from February 2001 to December 2002. 198 inpatients with cardiovascular diseases (94 BBT users and 104 non-users) in a university hospital were included in the study.
Users had a significantly higher level of education than non-users (college graduate: 28 [30%] versus 12 [12%], p = 0.003). Top 10 BBT products used were vitamin E [41(43.6%)], vitamin C [30(31.9%)], multivitamins [24(25.5%)], calcium [19(20.2%)], vitamin B complex [17(18.1%)], fish oil [12(12.8%)], coenzyme Q10 [11(11.7%)], glucosamine [10(10.6%)], magnesium [8(8.5%)] and vitamin D [6(6.4%)]. Sixty percent of users' physicians knew of the BBT use. Compared to non-users, users believed BBT to be safer (p < 0.001) and more effective (p < 0.001) than prescription drugs. Forty-two potential drug-BBT interactions were identified.
Incidence of use of BBT in cardiovascular patients is high (47.5%), as is the risk of potential drug interaction. Health care providers need to monitor BBT use in patients with cardiovascular diseases.
包括生物疗法（BBT）在内的补充和替代产品在患有各种疾病的患者中的使用有所增加。评估心血管疾病患者中BBT使用情况的研究有限。因此，对这一患者群体中的BBT进行评估将是有益的。这是一项旨在确定人口统计学因素对心血管疾病患者使用生物疗法（BBT）影响的调查。本研究的目的是确定教育水平对心血管疾病患者使用BBT的影响。该调查还评估了使用者对BBT安全性/有效性的看法、使用的BBT类型以及潜在的BBT与药物相互作用。
设计了调查工具来评估研究结果。在2001年2月至2002年12月期间对患者进行了访谈。一所大学医院的198名心血管疾病住院患者（94名BBT使用者和104名非使用者）被纳入研究。
使用者的教育水平显著高于非使用者（大学毕业生：28[30%]对12[12%]，p = 0.003）。使用最多的前10种BBT产品是维生素E[41（43.6%）]、维生素C[30（31.9%）]、多种维生素[24（25.5%）]、钙[19（20.2%）]、复合维生素B[17（18.1%）]、鱼油[12（12.8%）]、辅酶Q10[11（11.7%）]、葡萄糖胺[10（10.6%）]、镁[8（8.5%）]和维生素D[6（6.4%）]。60%使用者的医生知晓其使用BBT的情况。与非使用者相比，使用者认为BBT比处方药更安全（p < 0.001）且更有效（p < 0.001）。共识别出42种潜在的药物与BBT相互作用。
心血管疾病患者中BBT的使用率较高（47.5%），潜在药物相互作用的风险也较高。医疗保健提供者需要监测心血管疾病患者对BBT的使用情况。
